Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Keith Alan Johnson, M.D.

Co-Author

This page shows the publications co-authored by Keith Johnson and Rachel Buckley.
Connection Strength

3.517
  1. Sex Mediates Relationships Between Regional Tau Pathology and Cognitive Decline. Ann Neurol. 2020 11; 88(5):921-932.
    View in: PubMed
    Score: 0.229
  2. Using subjective cognitive decline to identify high global amyloid in community-based samples: A cross-cohort study. Alzheimers Dement (Amst). 2019 Dec; 11:670-678.
    View in: PubMed
    Score: 0.215
  3. Association of Amyloid and Tau With Cognition in Preclinical Alzheimer Disease: A Longitudinal Study. JAMA Neurol. 2019 Aug 01; 76(8):915-924.
    View in: PubMed
    Score: 0.213
  4. Sex Differences in the Association of Global Amyloid and Regional Tau Deposition Measured by Positron Emission Tomography in Clinically Normal Older Adults. JAMA Neurol. 2019 05 01; 76(5):542-551.
    View in: PubMed
    Score: 0.209
  5. Associations between baseline amyloid, sex, and APOE on subsequent tau accumulation in cerebrospinal fluid. Neurobiol Aging. 2019 06; 78:178-185.
    View in: PubMed
    Score: 0.207
  6. The impact of amyloid-beta and tau on prospective cognitive decline in older individuals. Ann Neurol. 2019 02; 85(2):181-193.
    View in: PubMed
    Score: 0.205
  7. Sex, amyloid, and APOE e4 and risk of cognitive decline in preclinical Alzheimer's disease: Findings from three well-characterized cohorts. Alzheimers Dement. 2018 09; 14(9):1193-1203.
    View in: PubMed
    Score: 0.196
  8. Region-Specific Association of Subjective Cognitive Decline With Tauopathy Independent of Global ß-Amyloid Burden. JAMA Neurol. 2017 12 01; 74(12):1455-1463.
    View in: PubMed
    Score: 0.190
  9. Functional network integrity presages cognitive decline in preclinical Alzheimer disease. Neurology. 2017 Jul 04; 89(1):29-37.
    View in: PubMed
    Score: 0.183
  10. A Conceptualization of the Utility of Subjective Cognitive Decline in Clinical Trials of Preclinical Alzheimer's Disease. J Mol Neurosci. 2016 Nov; 60(3):354-361.
    View in: PubMed
    Score: 0.173
  11. Unsupervised mobile cognitive testing for use in preclinical Alzheimer's disease. Alzheimers Dement (Amst). 2021; 13(1):e12243.
    View in: PubMed
    Score: 0.062
  12. Comparing PET and MRI Biomarkers Predicting Cognitive Decline in Preclinical Alzheimer Disease. Neurology. 2021 May 05.
    View in: PubMed
    Score: 0.060
  13. Diminished Learning Over Repeated Exposures (LORE) in preclinical Alzheimer's disease. Alzheimers Dement (Amst). 2020; 12(1):e12132.
    View in: PubMed
    Score: 0.059
  14. Defining the Lowest Threshold for Amyloid-PET to Predict Future Cognitive Decline and Amyloid Accumulation. Neurology. 2021 01 26; 96(4):e619-e631.
    View in: PubMed
    Score: 0.058
  15. Decline in cognitively complex everyday activities accelerates along the Alzheimer's disease continuum. Alzheimers Res Ther. 2020 10 29; 12(1):138.
    View in: PubMed
    Score: 0.058
  16. Identifying Sensitive Measures of Cognitive Decline at Different Clinical Stages of Alzheimer's Disease. J Int Neuropsychol Soc. 2021 05; 27(5):426-438.
    View in: PubMed
    Score: 0.058
  17. Resting-state functional connectivity and amyloid burden influence longitudinal cortical thinning in the default mode network in preclinical Alzheimer's disease. Neuroimage Clin. 2020; 28:102407.
    View in: PubMed
    Score: 0.057
  18. Multiple markers contribute to risk of progression from normal to mild cognitive impairment. Neuroimage Clin. 2020; 28:102400.
    View in: PubMed
    Score: 0.057
  19. Inferior temporal tau is associated with accelerated prospective cortical thinning in clinically normal older adults. Neuroimage. 2020 10 15; 220:116991.
    View in: PubMed
    Score: 0.056
  20. Functional and Pathological Correlates of Judgments of Learning in Cognitively Unimpaired Older Adults. Cereb Cortex. 2020 03 14; 30(3):1974-1983.
    View in: PubMed
    Score: 0.056
  21. Amyloid-beta burden predicts prospective decline in body mass index in clinically normal adults. Neurobiol Aging. 2020 09; 93:124-130.
    View in: PubMed
    Score: 0.055
  22. Clinical meaningfulness of subtle cognitive decline on longitudinal testing in preclinical AD. Alzheimers Dement. 2020 03; 16(3):552-560.
    View in: PubMed
    Score: 0.055
  23. Examining Cognitive Decline Across Black and White Participants in the Harvard Aging Brain Study. J Alzheimers Dis. 2020; 75(4):1437-1446.
    View in: PubMed
    Score: 0.055
  24. Longitudinal degradation of the default/salience network axis in symptomatic individuals with elevated amyloid burden. Neuroimage Clin. 2020; 26:102052.
    View in: PubMed
    Score: 0.054
  25. Associations of Physical Activity and ß-Amyloid With Longitudinal Cognition and Neurodegeneration in Clinically Normal Older Adults. JAMA Neurol. 2019 Oct 01; 76(10):1203-1210.
    View in: PubMed
    Score: 0.054
  26. Longitudinal Association of Depression Symptoms With Cognition and Cortical Amyloid Among Community-Dwelling Older Adults. JAMA Netw Open. 2019 08 02; 2(8):e198964.
    View in: PubMed
    Score: 0.053
  27. Synergism between fornix microstructure and beta amyloid accelerates memory decline in clinically normal older adults. Neurobiol Aging. 2019 09; 81:38-46.
    View in: PubMed
    Score: 0.052
  28. Global White Matter Diffusion Characteristics Predict Longitudinal Cognitive Change Independently of Amyloid Status in Clinically Normal Older Adults. Cereb Cortex. 2019 03 01; 29(3):1251-1262.
    View in: PubMed
    Score: 0.052
  29. Vascular Risk and ß-Amyloid Are Synergistically Associated with Cortical Tau. Ann Neurol. 2019 02; 85(2):272-279.
    View in: PubMed
    Score: 0.051
  30. An UNC5C Allele Predicts Cognitive Decline and Hippocampal Atrophy in Clinically Normal Older Adults. J Alzheimers Dis. 2019; 68(3):1161-1170.
    View in: PubMed
    Score: 0.051
  31. Nonlinear Distributional Mapping (NoDiM) for harmonization across amyloid-PET radiotracers. Neuroimage. 2019 02 01; 186:446-454.
    View in: PubMed
    Score: 0.051
  32. Amyloid-associated increases in longitudinal report of subjective cognitive complaints. Alzheimers Dement (N Y). 2018; 4:444-449.
    View in: PubMed
    Score: 0.050
  33. Interactive Associations of Vascular Risk and ß-Amyloid Burden With Cognitive Decline in Clinically Normal Elderly Individuals: Findings From the Harvard Aging Brain Study. JAMA Neurol. 2018 09 01; 75(9):1124-1131.
    View in: PubMed
    Score: 0.050
  34. PET staging of amyloidosis using striatum. Alzheimers Dement. 2018 10; 14(10):1281-1292.
    View in: PubMed
    Score: 0.049
  35. The relationship between recall of recently versus remotely encoded famous faces and amyloidosis in clinically normal older adults. Alzheimers Dement (Amst). 2018; 10:121-129.
    View in: PubMed
    Score: 0.047
  36. Neuroimaging markers associated with maintenance of optimal memory performance in late-life. Neuropsychologia. 2017 06; 100:164-170.
    View in: PubMed
    Score: 0.046
  37. Phases of Hyperconnectivity and Hypoconnectivity in the Default Mode and Salience Networks Track with Amyloid and Tau in Clinically Normal Individuals. J Neurosci. 2017 04 19; 37(16):4323-4331.
    View in: PubMed
    Score: 0.045
  38. The influence of demographic factors on subjective cognitive concerns and beta-amyloid. Int Psychogeriatr. 2017 04; 29(4):645-652.
    View in: PubMed
    Score: 0.044
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.